A Double-Blind, Randomized, Placebo-Controlled, Nonfasting Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Doses of ABT-450 With and Without Ritonavir.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Paritaprevir (Primary) ; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 28 Dec 2015 Results of pooled analysis from this and other phase I trial (see profile 46719), published in the British Journal of Clinical Pharmacology.
- 29 Jul 2009 Actual patient number (87) added as reported by ClinicalTrials.gov.
- 29 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.